
Performance · Recovery · Longevity
Catalogue
Browse “Muscle/Performamnce, Recovery/Tissue, Weight Loss/Metabolic and Research Peptides“ and advanced wellness compounds. Prices are shown in South African Rand (ZAR).
Select a product to view available quantities, specifications and regulatory status. Quantities, documentation and pricing are confirmed before dispatch.
CJC-1295 DAC (UPA Platinum)
|
Category: |
Muscle / GH / Performance |
|
SKU: |
TRW-CJC1295DAC |
|
Price: |
R 400.00 |
|
{{variant.name}}:
|
{{opt.name}}
{{opt.name}}
|
TEST RUN WELLNESS CJC-1295 with DAC | 2mg Long-Acting Peptide
CJC-1295 with DAC (2mg) – Long-acting Growth Hormone Releasing Hormone analogue. The added Drug Affinity Complex significantly extends the half-life, providing sustained GH and IGF-1 output for fat loss and muscle repair. Includes 2 ml bacteriostatic water.
Product Overview
CJC-1295 with DAC is a synthetic 30-amino-acid peptide analogue of Growth Hormone Releasing Hormone (GHRH). It incorporates four amino acid substitutions that confer resistance to enzymatic degradation, along with a Drug Affinity Complex (DAC) moiety — a maleimidopropionic acid linker that covalently binds to endogenous serum albumin after injection.
This bioconjugation dramatically increases the peptide‘s half-life to approximately 6–8 days in humans, enabling once- or twice-weekly dosing rather than the multiple daily injections required by non-DAC GHRH analogues.
How CJC-1295 with DAC Works: GHRH Receptor Agonist Pathway
CJC-1295 with DAC targets the growth hormone-releasing hormone receptor (GHRH-R), a G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary gland. Upon binding to this receptor, it mimics the action of endogenous GHRH and initiates an intracellular signaling cascade. The activated Gs protein dissociates and binds to adenylyl cyclase, converting ATP into cyclic AMP (cAMP).
The subsequent increase in intracellular cAMP activates Protein Kinase A (PKA), which phosphorylates downstream targets including the transcription factor CREB. CREB translocates to the nucleus and binds to promoter regions of target genes, stimulating both the synthesis of new growth hormone and the secretion of stored GH.
The DAC moiety does not alter receptor binding affinity but serves to prolong systemic exposure through covalent albumin association. Once conjugated, CJC-1295 with DAC remains active in the bloodstream for significantly longer than non-conjugated peptides that are rapidly excreted.
In clinical pharmacokinetic studies, a single subcutaneous injection of CJC-1295 with DAC produced mean GH concentrations increased approximately 2- to 10-fold for six days or longer, with mean IGF-1 concentrations increased approximately 1.5- to 3-fold for 9–11 days.
Following repeated administration, IGF-1 remained elevated above baseline for as long as 28 days. In one study, IGF-1 levels were increased in every subject one week after a single injection, with mean IGF-1 rising 44% from baseline.
Body Recomposition Benefits
CJC-1295 with DAC stimulates sustained elevation of growth hormone and its downstream effector, insulin-like growth factor 1 (IGF-1). GH and IGF-1 are anabolic hormones tied to protein synthesis, tissue repair, and lipolysis.
In research models, CJC-1295 with DAC has been used to study mechanisms of muscle growth and repair, as well as shifts in overall body composition toward increased lean mass and decreased fat mass. Studies in GHRH knockout mice demonstrated that CJC-1295 normalised relative lean mass and subcutaneous fat mass.
The prolonged GH/IGF-1 elevation achieved with the DAC version creates a sustained anabolic environment. Unlike non-DAC GHRH analogues that produce sharp, pulsatile GH bursts with a half-life of approximately 30 minutes, the DAC version maintains elevated baseline GH levels for days. This makes it particularly valuable for protocols targeting fat loss with lean mass preservation, muscle repair, and recovery support.
It should be noted that while CJC-1295 has demonstrated robust hormone-marker changes in clinical studies — including 2- to 10-fold GH increases and 1.5- to 3-fold IGF-1 increases — controlled human trials have not yet directly demonstrated improvements in body composition, muscle mass, or fat loss outcomes.
The marketed effects on body composition and recovery are inferred from the hormone rise rather than demonstrated directly in controlled human trials.
Titration Protocol
CJC-1295 with DAC is administered via subcutaneous injection. Because of its extended half-life of approximately 6–8 days, the DAC version is dosed far less frequently than the non-DAC variant. Standard protocols use 1,000 to 2,000 mcg (1–2 mg) per injection, once or twice per week, for cycles of 8–12 weeks.
A standard titration schedule is as follows:
· Week 1 (Ramp-up): 1 mg once weekly — establishes baseline tolerability
· Weeks 2–4: 1–2 mg once weekly — dose may be escalated based on IGF-1 response and tolerance
· Weeks 5–12 (Maintenance): 1–2 mg once weekly — most users find 1 mg sufficient; up to 2 mg weekly for advanced protocols
· Cycle completion: 8–12 weeks, followed by a washout period before repeat cycling
Subcutaneous administration into abdominal or thigh fat is standard. Injections are typically administered in a fasted state, with some researchers suggesting evening administration to synergise with the body‘s natural nocturnal GH pulses. Dose escalation should only proceed if the current dose is well tolerated.
Combination Therapy
CJC-1295 with DAC is commonly used as part of broader wellness and body recomposition protocols:
· CJC-1295 (no-DAC) + Ipamorelin: The most common GH secretagogue stack pairs the non-DAC version of CJC-1295 with Ipamorelin, a selective ghrelin mimetic.
CJC-1295 (no-DAC) provides rapid GHRH receptor activation while Ipamorelin triggers amplified GH pulses, typically at 100 mcg of each subcutaneously before bed on an empty stomach, 5 days on and 2 days off, for 8–12 weeks.
The DAC version is not typically combined with GHRPs due to risk of overstimulation from the sustained GH elevation.
· GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide): The theoretical rationale for combining CJC-1295 with GLP-1 therapies is that elevated GH and IGF-1 would shift the body composition response toward more fat loss and less lean mass loss during caloric deficit. CJC-1295 with DAC’s sustained GH/IGF-1 elevation may help preserve lean mass while GLP-1 agonists drive appetite suppression and fat loss.
· BPC-157: The combination of CJC-1295 with BPC-157 targets both systemic anabolic signaling and localized tissue repair. BPC-157‘s anti-inflammatory and healing properties complement CJC-1295’s GH/IGF-1-mediated repair mechanisms.
· MOTS-c: Stacked for metabolic optimization, combining GH/IGF-1 elevation with mitochondrial AMPK activation and enhanced fat oxidation.
All combination approaches should be pursued under professional medical supervision.
Clinical Trial Record
CJC-1295 with DAC was originally investigated for conditions including HIV-associated lipodystrophy and growth hormone deficiency. A Phase 2 clinical trial was conducted in subjects with HIV lipodystrophy by ConjuChem. Clinical development was discontinued following a serious adverse event in a trial subject.
In the pivotal pharmacokinetic study by Teichman et al. (2006) published in the Journal of Clinical Endocrinology & Metabolism, a single injection of CJC-1295 produced mean GH concentrations increased 2- to 10-fold for 6 or more days, with IGF-1 rising 1.5- to 3-fold for 9–11 days.
Following multiple doses, mean IGF-1 levels remained above baseline for up to 28 days. CJC-1295 with DAC is not FDA-approved for any indication and is classified as a research chemical.
Technical Specifications
· Product Name: CJC-1295 with DAC
· Peptide: CJC-1295 with Drug Affinity Complex (GHRH analogue)
· Concentration: 2mg per vial
· Form: Self-mix multi-dose vial
· Reconstitution: Requires bacteriostatic water for reconstitution (2ml included)
· Half-life: Approximately 6–8 days (albumin-bound)
· Administration: Subcutaneous injection, once or twice weekly
· Supplier: Test Run Wellness (Wellness.testrun)
⚕️ Important Medical Notice
Please consult your medical practitioner regarding your body requirements, as the dosing information provided contains guideline dosages. CJC-1295 with DAC is intended for use under professional medical supervision.
Regulatory notice. Test Run Wellness is an independent supplier and is not the manufacturer of the products referenced. No product should be used without appropriate regulatory authorisation and professional medical oversight.